Sartorius (0NIR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Dylan Van Haaften from Stifel Nicolaus maintained a Hold rating on the stock and has a €285.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Dylan Van Haaften’s rating is based on a mix of positive and negative factors influencing Sartorius’s performance. On the positive side, the company exceeded expectations in terms of EBITDA and order intake, particularly in its Bioprocess Solutions (BPS) segment, which showed strong growth and a solid order intake number. This segment’s performance suggests a potential for earnings upgrades in the future.
However, the Lab Products and Services (LPS) segment underperformed, missing revenue and EBITDA estimates due to reduced purchasing and R&D retrenchment in key sectors like NIH, academia, and pharma/biotech. This weakness in LPS, coupled with the absence of an explicit order intake number and a wide guidance range, introduces uncertainty. These mixed signals contribute to the Hold rating, indicating that while there are positive developments, there are also risks that need to be carefully monitored.
According to TipRanks, Van Haaften is ranked #8393 out of 9350 analysts.
In another report released today, Jefferies also maintained a Hold rating on the stock with a €264.00 price target.